Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2008

01-07-2008 | Original Article

18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?

Authors: Ruoh-Fang Yen, Ke-Cheng Chen, Jang-Ming Lee, Yeun-Chung Chang, Jane Wang, Mei-Fang Cheng, Yen-Wen Wu, Yung-Chie Lee

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2008

Login to get access

Abstract

Purpose

This study was to compare 18F-FDG positron emission tomography (PET) with thoracic contrast-enhanced CT (CECT) in the ability of lymph node (LN) staging non-small cell lung cancer (NSCLC) in a tuberculosis-prevalent country. The usefulness of dual time point PET imaging (DTPI) in NSCLC nodal staging was also evaluated.

Methods

We reviewed 96 NSCLC patients (mean age, 65.3 ± 11.7 years) who had received PET studies before their surgery. DTPI were performed on 37 patients (mean age, 64.8 ± 12.2 years) who received an additional scan of thorax 3 h after tracer injection. The accuracies of nodal staging by CECT and PET were evaluated according to final histopathology of hilar and mediastinal LN resected by surgery.

Results

The accuracy for nodal staging by CECT was 65.6% and that by PET was 82.3% (p < 0.05). Six patients were over-staged and 11 were under-staged by PET. Tuberculosis (n = 3, 50%) were mostly responsible for false-positive, while small tumor foci (n = 7, 63.6%) were mostly accountable for false-negative. For the 37 patients with DTPI, 45 min standardized uptake value (SUV) and 3 h SUV for negative LNs are significantly lower than those for positive LNs (p < 0.0001). Nevertheless, the retention index (RI) showed no significant difference between these two groups.

Conclusions

Our study demonstrates that PET is more accurate than CECT in LN staging NSCLC patients in Taiwan where TB is still prevalent. Semi-quantitative SUV method or DTPI with RI does not result in better diagnostic accuracy than visual analysis of PET images.
Literature
1.
go back to reference Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–7.PubMedCrossRef Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–7.PubMedCrossRef
2.
go back to reference Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 1999;117:593–8.PubMedCrossRef Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 1999;117:593–8.PubMedCrossRef
3.
go back to reference Takamochi K, Nagai K, Yoshida J, Suzuki K, Ohde Y, Nishimura M, et al. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000;119:1135–40.PubMedCrossRef Takamochi K, Nagai K, Yoshida J, Suzuki K, Ohde Y, Nishimura M, et al. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000;119:1135–40.PubMedCrossRef
4.
go back to reference Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med. 1978;19:1154–61.PubMed Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med. 1978;19:1154–61.PubMed
5.
go back to reference Birim Ö, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79:375–82.PubMedCrossRef Birim Ö, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79:375–82.PubMedCrossRef
6.
go back to reference Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 1999;213:530–6.PubMed Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 1999;213:530–6.PubMed
7.
go back to reference Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.PubMed Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.PubMed
8.
go back to reference Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004;9:633–43.PubMedCrossRef Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004;9:633–43.PubMedCrossRef
9.
go back to reference Schmucking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res. 2003;162:195–202.PubMed Schmucking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res. 2003;162:195–202.PubMed
10.
go back to reference Saunders CAB, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790–7.PubMedCrossRef Saunders CAB, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790–7.PubMedCrossRef
11.
go back to reference Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.PubMedCrossRef Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.PubMedCrossRef
12.
go back to reference Kramer H, Post WJ, Pruim J, Groen HJ. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer. 2006;52:213–7.PubMedCrossRef Kramer H, Post WJ, Pruim J, Groen HJ. The prognostic value of positron emission tomography in non-small cell lung cancer: analysis of 266 cases. Lung Cancer. 2006;52:213–7.PubMedCrossRef
13.
go back to reference Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg. 2000;70:1154–9.PubMedCrossRef Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg. 2000;70:1154–9.PubMedCrossRef
14.
go back to reference Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521–7.PubMedCrossRef Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120:521–7.PubMedCrossRef
15.
go back to reference Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500–6.PubMedCrossRef Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500–6.PubMedCrossRef
16.
go back to reference Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235–42.PubMedCrossRef Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235–42.PubMedCrossRef
17.
go back to reference Patz EF Jr., Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617–21.PubMedCrossRef Patz EF Jr., Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617–21.PubMedCrossRef
18.
go back to reference Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed
19.
go back to reference Chiu YS, Wang JT, Chang SC, Tang JL, Ku SC, Hung CC, et al. Mycobacterium tuberculosis bacteremia in HIV-negative patients. J Formos Med Assoc. 2007;106:355–64.PubMed Chiu YS, Wang JT, Chang SC, Tang JL, Ku SC, Hung CC, et al. Mycobacterium tuberculosis bacteremia in HIV-negative patients. J Formos Med Assoc. 2007;106:355–64.PubMed
20.
go back to reference Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed
21.
go back to reference Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed
22.
go back to reference Dumont P, Gasser B, Rougé C, Massard G, Wihlm JM. Bronchoalveolar carcinoma. Histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998;113:391–5.PubMedCrossRef Dumont P, Gasser B, Rougé C, Massard G, Wihlm JM. Bronchoalveolar carcinoma. Histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998;113:391–5.PubMedCrossRef
23.
go back to reference Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705–13.PubMed Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705–13.PubMed
24.
go back to reference Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–9.PubMed
25.
go back to reference Watanabe A, Koyanagi T, Ohsawa H, Mawatari T, Nakashima S, Takahashi N, et al. Systematic node dissection by VATS is not inferior to that through an open thoracotomy: a comparative clinicopathologic retrospective study. Surgery 2005;138:510–7.PubMedCrossRef Watanabe A, Koyanagi T, Ohsawa H, Mawatari T, Nakashima S, Takahashi N, et al. Systematic node dissection by VATS is not inferior to that through an open thoracotomy: a comparative clinicopathologic retrospective study. Surgery 2005;138:510–7.PubMedCrossRef
26.
go back to reference Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50:1267–9.PubMedCrossRef Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50:1267–9.PubMedCrossRef
27.
go back to reference Arita T, Matsumoto T, Kuramitsu T, Kawamura M, Matsunaga N, Sugi K, et al. Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 1996;110:1004–8.PubMedCrossRef Arita T, Matsumoto T, Kuramitsu T, Kawamura M, Matsunaga N, Sugi K, et al. Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen. Chest 1996;110:1004–8.PubMedCrossRef
28.
go back to reference Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996;111:642–8.PubMedCrossRef Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996;111:642–8.PubMedCrossRef
29.
go back to reference Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142–9.PubMed Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142–9.PubMed
30.
go back to reference Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Højgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697–702.PubMedCrossRef Fischer BM, Olsen MW, Ley CD, Klausen TL, Mortensen J, Højgaard L, et al. How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging 2006;33:697–702.PubMedCrossRef
31.
go back to reference Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011–9.PubMedCrossRef Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011–9.PubMedCrossRef
32.
go back to reference Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer 2007;109:1068–77.PubMedCrossRef Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer 2007;109:1068–77.PubMedCrossRef
Metadata
Title
18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?
Authors
Ruoh-Fang Yen
Ke-Cheng Chen
Jang-Ming Lee
Yeun-Chung Chang
Jane Wang
Mei-Fang Cheng
Yen-Wen Wu
Yung-Chie Lee
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0733-1

Other articles of this Issue 7/2008

European Journal of Nuclear Medicine and Molecular Imaging 7/2008 Go to the issue